{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:53:19Z","timestamp":1781549599624,"version":"3.54.5"},"reference-count":23,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"12","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Varicella (chickenpox) is a ubiquitous disease of childhood in the UK, yet highly effective and safe vaccines have been routinely used in other countries for years. Previous UK assessments of varicella vaccines did not meet the National Institute of Health and Care Excellence \u00a320\u201330k\/quality-adjusted life year (QALY) cost utility threshold, in part due to limited data quantifying the quality of life (QoL) lost.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We carried out a prospective multicenter observational study recruiting families while their child had acute varicella or secondary complications. We recruited severe cases admitted to hospital and mild community cases from childcare. QoL was assessed using standard tools: EQ5D-5L + CHU9 for children and EQ5D-5L for both carers. Assessments were carried out daily in the hospitalized arm until discharge, weekly for 1 month and then at 6 months. In the community arm, assessments were daily until back to normal health.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Between 2018 and 2022, we obtained data on 55 community and 140 hospitalized cases. Mean QALY loss in children was 6.7 (6.1\u20137.0)\/1000 community cases and 46.7 [95% confidence interval (CI): 44.5\u201351.6]\/1000 hospitalized. Primary carers lost 2.4 (95% CI: 2.2\u20132.8)\/1000 community cases or 20.2 (95% CI: 19.4\u201322.3)\/1000 hospitalized. Secondary carers lost 0.7 (0.3\u20130.7)\/1000 community cases or 15.8 (95% CI: 15.5\u201318.1)\/1000 hospitalized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>This detailed prospective assessment of QoL loss from varicella found it to be 1.5\u201310\u00d7 larger in children than used in previous economic assessments and quantified the QALY loss for both primary and secondary carers. These data have been used to parameterize new assessments of UK varicella vaccine cost utility.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/inf.0000000000004967","type":"journal-article","created":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T22:00:10Z","timestamp":1758232810000},"page":"1244-1249","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Quality of Life Impact of Varicella on Children and Their Families in the UK: The QoLPoX Study"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3192-3102","authenticated-orcid":false,"given":"Robin","family":"Marlow","sequence":"first","affiliation":[{"name":"Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust"},{"name":"Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Roderick","sequence":"additional","affiliation":[{"name":"Bristol Royal Hospital for Children, University Hospitals Bristol and Weston NHS Foundation Trust"},{"name":"Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Oliver","sequence":"additional","affiliation":[{"name":"Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoe","family":"Jordan","sequence":"additional","affiliation":[{"name":"Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabel","family":"Rowbotham","sequence":"additional","affiliation":[{"name":"Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Jones","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Royal United Hospital, Bath"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Royal Devon and Exeter NHS Foundation Trust, Exeter"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clara","family":"Thompson","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Gloucestershire Hospitals NHS Foundation Trust, Gloucester"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liz","family":"Whittaker","sequence":"additional","affiliation":[{"name":"Paediatric Infectious Diseases, Imperial College Healthcare NHS Trust"},{"name":"Section of Paediatric Infectious Diseases, Imperial College London, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Bethell","sequence":"additional","affiliation":[{"name":"Oxford University Hospitals NHS Foundation Trust, Oxford"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiona","family":"Shackley","sequence":"additional","affiliation":[{"name":"Paediatric Immunology and Infectious Disease, Sheffield Children\u2019s NHS Foundation Trust, Sheffield"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrina","family":"Cathie","sequence":"additional","affiliation":[{"name":"NIHR Southampton Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, Southampton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul T.","family":"Heath","sequence":"additional","affiliation":[{"name":"Centre for Neonatal and Paediatric infection, St George\u2019s, University of London, London"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Langlands","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Musgrove Park Hospital, Somerset NHS Foundation Trust, Taunton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamie","family":"Lopez-Bernal","sequence":"additional","affiliation":[{"name":"Department of Paediatrics, Musgrove Park Hospital, Somerset NHS Foundation Trust, Taunton"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gayatri","family":"Amirthalingam","sequence":"additional","affiliation":[{"name":"Immunisation and Vaccine Preventable Diseases Division, UK Health Security Agency, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernanda","family":"Rodrigues","sequence":"additional","affiliation":[{"name":"Paediatric Emergency Service and Infectious Diseases Unit, Hospital Pedi\u00e1trico, ULS Coimbra"},{"name":"Faculdade de Medicina, Universidade de Coimbra, Coimbra, Portugal."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Finn","sequence":"additional","affiliation":[{"name":"Bristol Vaccine Centre, Schools of Population Health Sciences and of Cellular and Molecular Medicine, University of Bristol, Bristol"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the QoLPoX Research Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,9,12]]},"reference":[{"key":"R1-20260615","first-page":"265","article-title":"Varicella and herpes zoster vaccines: WHO position paper, June 2014.","volume":"89","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"key":"R3-20260615","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/cid\/ciy1099","article-title":"Systematic review and meta-analysis of chickenpox vaccination and risk of herpes zoster: a quantitative view on the \u201cexogenous boosting hypothesis\u201d.","volume":"69","author":"Harder","year":"2019","journal-title":"Clin Infect Dis"},{"key":"R4-20260615","doi-asserted-by":"crossref","first-page":"e076321","DOI":"10.1136\/bmj-2023-076321","article-title":"Effectiveness of the live zoster vaccine during the 10 years following vaccination: real world cohort study using electronic health records.","volume":"383","author":"Klein","year":"2023","journal-title":"BMJ"},{"key":"R5-20260615","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/cid\/ciab125","article-title":"Recombinant Zoster Vaccine (Shingrix): real-world effectiveness in the first 2 years post-licensure.","volume":"73","author":"Izurieta","year":"2021","journal-title":"Clin Infect Dis"},{"key":"R8-20260615","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/adc.88.10.862","article-title":"Varicella vaccination in England and Wales: cost-utility analysis.","volume":"88","author":"Brisson","year":"2003","journal-title":"Arch Dis Child"},{"key":"R9-20260615","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1017\/S0950268811002640","article-title":"The health and economic burden of chickenpox and herpes zoster in Belgium.","volume":"140","author":"Bilcke","year":"2012","journal-title":"Epidemiol Infect"},{"key":"R11-20260615","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol\u2014a new facility for the measurement of health-related quality of life.","volume":"16","year":"1990","journal-title":"Health Policy"},{"key":"R12-20260615","doi-asserted-by":"crossref","first-page":"729","DOI":"10.2165\/11599120-000000000-00000","article-title":"Valuation of the child health utility 9D index.","volume":"30","author":"Stevens","year":"2012","journal-title":"PharmacoEcon"},{"key":"R13-20260615","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2014a metadata-driven methodology and workflow process for providing translational research informatics support.","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"R14-20260615","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: building an international community of software platform partners.","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"R15-20260615","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","article-title":"Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets.","volume":"15","author":"van Hout","year":"2012","journal-title":"Value Health"},{"key":"R16-20260615","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S0140-6736(86)90837-8","article-title":"Statistical methods for assessing agreement between two methods of clinical measurement.","volume":"1","author":"Bland","year":"1986","journal-title":"Lancet"},{"key":"R17-20260615","doi-asserted-by":"crossref","first-page":"e068611","DOI":"10.1136\/bmjopen-2022-068611","article-title":"Epidemiology of hospitalisations due to chickenpox and quality of life lost in community and hospital settings: protocol for a prospective cohort study across two countries.","volume":"13","author":"Marlow","year":"2023","journal-title":"BMJ Open"},{"key":"R18-20260615","doi-asserted-by":"crossref","first-page":"5212","DOI":"10.1016\/j.vaccine.2015.07.012","article-title":"Quality of life impacts from rotavirus gastroenteritis on children and their families in the UK.","volume":"33","author":"Marlow","year":"2015","journal-title":"Vaccine"},{"key":"R19-20260615","doi-asserted-by":"crossref","first-page":"4203","DOI":"10.1016\/j.vaccine.2004.05.003","article-title":"Cost-effectiveness analysis of pneumococcal conjugate vaccination in England and Wales.","volume":"22","author":"Melegaro","year":"2004","journal-title":"Vaccine"},{"key":"R20-20260615","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1016\/j.vaccine.2023.03.024","article-title":"Economic burden and health-related quality-of-life among infants with respiratory syncytial virus infection: a multi-country prospective cohort study in Europe.","volume":"41","author":"Mao","year":"2023","journal-title":"Vaccine"},{"key":"R21-20260615","doi-asserted-by":"crossref","first-page":"e17030","DOI":"10.1371\/journal.pone.0017030","article-title":"The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study.","volume":"6","author":"van Hoek","year":"2011","journal-title":"PLoS One"},{"key":"R22-20260615","doi-asserted-by":"crossref","first-page":"e105153","DOI":"10.1371\/journal.pone.0105153","article-title":"The effect of measles on health-related quality of life: a patient-based survey.","volume":"9","author":"Thorrington","year":"2014","journal-title":"PLoS One"},{"key":"R23-20260615","doi-asserted-by":"crossref","first-page":"e111807","DOI":"10.1371\/journal.pone.0111807","article-title":"The burden of disease and health care use among pertussis cases in school aged children and adults in England and Wales; a patient survey.","volume":"9","author":"van Hoek","year":"2014","journal-title":"PLoS One"},{"key":"R24-20260615","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ"},{"key":"R25-20260615","doi-asserted-by":"crossref","first-page":"e037089","DOI":"10.1136\/bmjopen-2020-037089","article-title":"Comparison of the CHU-9D and the EQ-5D-Y instruments in children and young people with cerebral palsy: a cross-sectional study.","volume":"10","author":"Ryan","year":"2020","journal-title":"BMJ Open"},{"key":"R26-20260615","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1186\/s41687-020-00251-4","article-title":"Validity and reliability testing of the Toddler and Infant (TANDI) health related quality of life instrument for very young children.","volume":"4","author":"Verstraete","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"R27-20260615","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1016\/j.vaccine.2022.12.011","article-title":"Prospective study of loss of health-related quality adjusted life years in children and their families due to uncomplicated and hospitalised varicella.","volume":"41","author":"Rodrigues","year":"2023","journal-title":"Vaccine"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004967","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T18:01:01Z","timestamp":1781546461000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004967","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"value":"0891-3668","type":"print"},{"value":"1532-0987","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,12]]}}}